[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiAbdF7KueEC7j_u2Se9l-FOukN_1Y2H69g2j_KM-MM4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Procter and Gamble",[4],83,false,2,6,24583,5,34,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Gingivitis",22,{"name":18,"count":19},"Dentin Sensitivity",9,{"name":21,"count":11},"Dental Plaque",{"name":23,"count":24},"Healthy",4,{"name":26,"count":24},"Caries",{"name":28,"count":24},"Plaque",{"name":30,"count":8},"Menstruation",{"name":32,"count":8},"Subgingival Plaque",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06962956","Evaluating Gingivitis and Systemic Biomarkers","2025-10-31","0.76% Sodium Monofluorophosphate Dentifrice",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07158112","Assessing Gingivitis and Plaque From a Marketed Toothpaste","2025-12-07","Stannous Fluoride Dentifrice",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,87,105,173,222,252,287,309,331,368,390,412,434,452,470,495,520,538,564,582,607,632,650,675,701,719,744,786,812,837,855,873,900,928,946,964,982,1006,1059,1089,1119,1161,1202,1248,1270,1292,1314,1336,1354,1372,1401,1419,1437,1455,1473,1491,1518,1536,1554,1572,1590,1613,1638,1656,1674,1692,1710,1735],{"intervention":53,"totalTrials":8,"cells":54},"Sodium monofluorophosphate dentifrice",{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":73,"PHASE4":75,"NA":85},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[62],{"nctId":63,"briefTitle":64,"status":65,"phases":66,"primaryCompletion":67,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":71},"NCT06892834","Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.","COMPLETED",[47],"2025-06-19","2025-03-25",120,[15],[43,72,53],"Sodium Fluoride Dentifrice",{"trials":74,"activeCount":57},[],{"trials":76,"activeCount":84,"soonestReadout":42},[77],{"nctId":40,"briefTitle":41,"status":78,"phases":79,"primaryCompletion":42,"completion":42,"start":80,"enrollment":69,"conditions":81,"interventions":82},"ACTIVE_NOT_RECRUITING",[49],"2025-08-30",[15],[43,83,53],"Test Stannous Fluoride Dentifrice",1,{"trials":86,"activeCount":57},[],{"intervention":83,"totalTrials":84,"cells":88},{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":95,"PHASE4":97,"NA":103},{"trials":90,"activeCount":57},[],{"trials":92,"activeCount":57},[],{"trials":94,"activeCount":57},[],{"trials":96,"activeCount":57},[],{"trials":98,"activeCount":84,"soonestReadout":42},[99],{"nctId":40,"briefTitle":41,"status":78,"phases":100,"primaryCompletion":42,"completion":42,"start":80,"enrollment":69,"conditions":101,"interventions":102},[49],[15],[43,83,53],{"trials":104,"activeCount":57},[],{"intervention":43,"totalTrials":106,"cells":107},7,{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":118,"PHASE4":120,"NA":136},{"trials":109,"activeCount":57},[],{"trials":111,"activeCount":57},[],{"trials":113,"activeCount":57},[114],{"nctId":63,"briefTitle":64,"status":65,"phases":115,"primaryCompletion":67,"completion":67,"start":68,"enrollment":69,"conditions":116,"interventions":117},[47],[15],[43,72,53],{"trials":119,"activeCount":57},[],{"trials":121,"activeCount":84,"soonestReadout":42},[122,132],{"nctId":123,"briefTitle":124,"status":65,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT07211061","A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods",[49],"2011-11-10","2011-09-21",69,[15],[43,72,131],"Cetylpyridinium Chloride",{"nctId":40,"briefTitle":41,"status":78,"phases":133,"primaryCompletion":42,"completion":42,"start":80,"enrollment":69,"conditions":134,"interventions":135},[49],[15],[43,83,53],{"trials":137,"activeCount":57},[138,151,158,165],{"nctId":139,"briefTitle":140,"status":65,"phases":141,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":147},"NCT04005417","Meta-analysis of Stannous Fluoride Dentifrice and the Effects on Dentine Hypersensitivity",[],"2018-11-30","2018-01-08",1036,[146],"Dentine Hypersensitivity",[148,149,150],"Stannous fluoride dentifrice","Positive control dentifrice","Negative control dentifrice",{"nctId":152,"briefTitle":153,"status":65,"phases":154,"primaryCompletion":142,"completion":142,"start":143,"enrollment":155,"conditions":156,"interventions":157},"NCT04006483","Meta-analysis of Stannous Fluoride and the Effects on Dental Plaque",[],2359,[21],[148,149,150],{"nctId":159,"briefTitle":160,"status":65,"phases":161,"primaryCompletion":142,"completion":142,"start":143,"enrollment":162,"conditions":163,"interventions":164},"NCT03970759","Meta-analysis of Stannous Fluoride and the Effects on Gingival Health",[],2890,[15],[43,149,150],{"nctId":166,"briefTitle":167,"status":65,"phases":168,"primaryCompletion":142,"completion":142,"start":143,"enrollment":169,"conditions":170,"interventions":172},"NCT04006470","Meta-analysis of Stannous Fluoride and the Effects on Enamel Erosion",[],172,[171],"Enamel Erosion",[148,149,150],{"intervention":38,"totalTrials":24,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":176,"activeCount":57},[],{"trials":178,"activeCount":84,"soonestReadout":37},[179],{"nctId":35,"briefTitle":36,"status":78,"phases":180,"primaryCompletion":37,"completion":37,"start":181,"enrollment":182,"conditions":183,"interventions":184},[46],"2025-04-30",135,[15],[38,185,185],"0.454% Stannous Fluoride Dentifrice",{"trials":187,"activeCount":57},[],{"trials":189,"activeCount":57},[],{"trials":191,"activeCount":57},[],{"trials":193,"activeCount":57},[194,204,213],{"nctId":195,"briefTitle":196,"status":65,"phases":197,"primaryCompletion":198,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":202},"NCT06140771","A Clinical Study to Assess the Gingivitis Effects of Various Dentifrices",[50],"2022-02-06","2021-10-20",115,[15],[38,203,185,185],"1.15% Sodium Monofluorophosphate Dentifrice",{"nctId":205,"briefTitle":206,"status":65,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},"NCT06140784","A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices",[50],"2023-12-10","2023-09-02",116,[15],[38,185,185,185],{"nctId":214,"briefTitle":215,"status":65,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":69,"conditions":219,"interventions":221},"NCT06659471","Brief Title: a Clinical Study to Assess Gingivitis",[50],"2022-06-06","2022-03-07",[220],"Gingival Diseases",[38,185],{"intervention":185,"totalTrials":24,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":238},{"trials":225,"activeCount":57},[],{"trials":227,"activeCount":84,"soonestReadout":37},[228],{"nctId":35,"briefTitle":36,"status":78,"phases":229,"primaryCompletion":37,"completion":37,"start":181,"enrollment":182,"conditions":230,"interventions":231},[46],[15],[38,185,185],{"trials":233,"activeCount":57},[],{"trials":235,"activeCount":57},[],{"trials":237,"activeCount":57},[],{"trials":239,"activeCount":57},[240,244,248],{"nctId":195,"briefTitle":196,"status":65,"phases":241,"primaryCompletion":198,"completion":198,"start":199,"enrollment":200,"conditions":242,"interventions":243},[50],[15],[38,203,185,185],{"nctId":205,"briefTitle":206,"status":65,"phases":245,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":246,"interventions":247},[50],[15],[38,185,185,185],{"nctId":214,"briefTitle":215,"status":65,"phases":249,"primaryCompletion":217,"completion":217,"start":218,"enrollment":69,"conditions":250,"interventions":251},[50],[220],[38,185],{"intervention":253,"totalTrials":8,"cells":254},"Marketed Toothpaste",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":285},{"trials":256,"activeCount":57},[],{"trials":258,"activeCount":57},[],{"trials":260,"activeCount":57},[],{"trials":262,"activeCount":57},[],{"trials":264,"activeCount":57},[265,275],{"nctId":266,"briefTitle":267,"status":65,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT03936569","A Clinical Study to Assess the Plaque and Gingivitis Effects of a Stannous Fluoride Dentifrice",[49],"2019-01-25","2018-10-29",90,[15],[253,274],"Marketed Cavity Protection Toothpaste",{"nctId":276,"briefTitle":277,"status":65,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT03936556","A Clinical Study to Assess the Effects of a Stannous Fluoride Dentifrice on Plaque and Gingivitis",[49],"2018-06-03","2018-02-25",84,[15],[284,274],"Marketed toothpaste",{"trials":286,"activeCount":57},[],{"intervention":274,"totalTrials":8,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":307},{"trials":290,"activeCount":57},[],{"trials":292,"activeCount":57},[],{"trials":294,"activeCount":57},[],{"trials":296,"activeCount":57},[],{"trials":298,"activeCount":57},[299,303],{"nctId":266,"briefTitle":267,"status":65,"phases":300,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":301,"interventions":302},[49],[15],[253,274],{"nctId":276,"briefTitle":277,"status":65,"phases":304,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":305,"interventions":306},[49],[15],[284,274],{"trials":308,"activeCount":57},[],{"intervention":72,"totalTrials":8,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":321,"PHASE4":323,"NA":329},{"trials":312,"activeCount":57},[],{"trials":314,"activeCount":57},[],{"trials":316,"activeCount":57},[317],{"nctId":63,"briefTitle":64,"status":65,"phases":318,"primaryCompletion":67,"completion":67,"start":68,"enrollment":69,"conditions":319,"interventions":320},[47],[15],[43,72,53],{"trials":322,"activeCount":57},[],{"trials":324,"activeCount":57},[325],{"nctId":123,"briefTitle":124,"status":65,"phases":326,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":327,"interventions":328},[49],[15],[43,72,131],{"trials":330,"activeCount":57},[],{"intervention":332,"totalTrials":8,"cells":333},"0 ppm F",{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":350,"PHASE3":352,"PHASE4":354,"NA":366},{"trials":335,"activeCount":57},[],{"trials":337,"activeCount":57},[338],{"nctId":339,"briefTitle":340,"status":65,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":346},"NCT06735235","Salivary Fluoride Clearance",[46],"2021-07-29","2021-07-14",27,[26],[332,347,348,349],"250 ppm F as MFP","1100 ppm as MFP","2800 ppm F as MFP",{"trials":351,"activeCount":57},[],{"trials":353,"activeCount":57},[],{"trials":355,"activeCount":57},[356],{"nctId":357,"briefTitle":358,"status":65,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":364},"NCT04763044","Evaluation of the Fluoride Dose Response Using In Situ Caries Model",[49],"2021-07-21","2021-03-01",15,[26],[332,347,348,349,365],"1100 ppm SnF2",{"trials":367,"activeCount":57},[],{"intervention":347,"totalTrials":8,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":388},{"trials":371,"activeCount":57},[],{"trials":373,"activeCount":57},[374],{"nctId":339,"briefTitle":340,"status":65,"phases":375,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":376,"interventions":377},[46],[26],[332,347,348,349],{"trials":379,"activeCount":57},[],{"trials":381,"activeCount":57},[],{"trials":383,"activeCount":57},[384],{"nctId":357,"briefTitle":358,"status":65,"phases":385,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":386,"interventions":387},[49],[26],[332,347,348,349,365],{"trials":389,"activeCount":57},[],{"intervention":348,"totalTrials":8,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":410},{"trials":393,"activeCount":57},[],{"trials":395,"activeCount":57},[396],{"nctId":339,"briefTitle":340,"status":65,"phases":397,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":398,"interventions":399},[46],[26],[332,347,348,349],{"trials":401,"activeCount":57},[],{"trials":403,"activeCount":57},[],{"trials":405,"activeCount":57},[406],{"nctId":357,"briefTitle":358,"status":65,"phases":407,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":408,"interventions":409},[49],[26],[332,347,348,349,365],{"trials":411,"activeCount":57},[],{"intervention":349,"totalTrials":8,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":422,"PHASE3":424,"PHASE4":426,"NA":432},{"trials":415,"activeCount":57},[],{"trials":417,"activeCount":57},[418],{"nctId":339,"briefTitle":340,"status":65,"phases":419,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":420,"interventions":421},[46],[26],[332,347,348,349],{"trials":423,"activeCount":57},[],{"trials":425,"activeCount":57},[],{"trials":427,"activeCount":57},[428],{"nctId":357,"briefTitle":358,"status":65,"phases":429,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":430,"interventions":431},[49],[26],[332,347,348,349,365],{"trials":433,"activeCount":57},[],{"intervention":131,"totalTrials":84,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":444,"NA":450},{"trials":437,"activeCount":57},[],{"trials":439,"activeCount":57},[],{"trials":441,"activeCount":57},[],{"trials":443,"activeCount":57},[],{"trials":445,"activeCount":57},[446],{"nctId":123,"briefTitle":124,"status":65,"phases":447,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":448,"interventions":449},[49],[15],[43,72,131],{"trials":451,"activeCount":57},[],{"intervention":365,"totalTrials":84,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":468},{"trials":455,"activeCount":57},[],{"trials":457,"activeCount":57},[],{"trials":459,"activeCount":57},[],{"trials":461,"activeCount":57},[],{"trials":463,"activeCount":57},[464],{"nctId":357,"briefTitle":358,"status":65,"phases":465,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":466,"interventions":467},[49],[26],[332,347,348,349,365],{"trials":469,"activeCount":57},[],{"intervention":471,"totalTrials":84,"cells":472},"Diphenhydramine Hydrochloride",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":493},{"trials":474,"activeCount":57},[],{"trials":476,"activeCount":57},[],{"trials":478,"activeCount":57},[],{"trials":480,"activeCount":57},[],{"trials":482,"activeCount":57},[483],{"nctId":484,"briefTitle":485,"status":65,"phases":486,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":492},"NCT02578186","Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness",[49],"2014-12","2013-11",33,[491],"Occasional Sleeplessness",[471],{"trials":494,"activeCount":57},[],{"intervention":496,"totalTrials":84,"cells":497},"Prilosec OTC",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":518},{"trials":499,"activeCount":57},[],{"trials":501,"activeCount":57},[],{"trials":503,"activeCount":57},[],{"trials":505,"activeCount":57},[],{"trials":507,"activeCount":57},[508],{"nctId":509,"briefTitle":510,"status":65,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":516},"NCT00903448","Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression",[49],"2009-06","2009-04",40,[23],[496,517],"Prevacid",{"trials":519,"activeCount":57},[],{"intervention":517,"totalTrials":84,"cells":521},{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":536},{"trials":523,"activeCount":57},[],{"trials":525,"activeCount":57},[],{"trials":527,"activeCount":57},[],{"trials":529,"activeCount":57},[],{"trials":531,"activeCount":57},[532],{"nctId":509,"briefTitle":510,"status":65,"phases":533,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":534,"interventions":535},[49],[23],[496,517],{"trials":537,"activeCount":57},[],{"intervention":539,"totalTrials":84,"cells":540},"Zegerid®",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":549,"NA":562},{"trials":542,"activeCount":57},[],{"trials":544,"activeCount":57},[],{"trials":546,"activeCount":57},[],{"trials":548,"activeCount":57},[],{"trials":550,"activeCount":57},[551],{"nctId":552,"briefTitle":553,"status":65,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT00808769","Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression",[49],"2008-12","2008-11",30,[559],"Normal Healthy Subject Population",[539,561],"Prilosec OTC®",{"trials":563,"activeCount":57},[],{"intervention":561,"totalTrials":84,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":574,"NA":580},{"trials":567,"activeCount":57},[],{"trials":569,"activeCount":57},[],{"trials":571,"activeCount":57},[],{"trials":573,"activeCount":57},[],{"trials":575,"activeCount":57},[576],{"nctId":552,"briefTitle":553,"status":65,"phases":577,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":578,"interventions":579},[49],[559],[539,561],{"trials":581,"activeCount":57},[],{"intervention":583,"totalTrials":84,"cells":584},"Pexelizumab",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":603,"NA":605},{"trials":586,"activeCount":57},[],{"trials":588,"activeCount":57},[],{"trials":590,"activeCount":57},[],{"trials":592,"activeCount":57},[593],{"nctId":594,"briefTitle":595,"status":65,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":602},"NCT00091637","Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)",[48],"2007-05","2004-04",5745,[601],"Acute Myocardial Infarction",[583],{"trials":604,"activeCount":57},[],{"trials":606,"activeCount":57},[],{"intervention":608,"totalTrials":84,"cells":609},"Preventive Gel",{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":628,"NA":630},{"trials":611,"activeCount":57},[],{"trials":613,"activeCount":57},[],{"trials":615,"activeCount":57},[],{"trials":617,"activeCount":57},[618],{"nctId":619,"briefTitle":620,"status":65,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT03546491","Evaluate Dental Plaque Benefit of a Preventive Treatment Gel",[48],"2018-06-22","2018-05-08",32,[21],[608,627],"Marketed Control",{"trials":629,"activeCount":57},[],{"trials":631,"activeCount":57},[],{"intervention":627,"totalTrials":84,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":646,"NA":648},{"trials":635,"activeCount":57},[],{"trials":637,"activeCount":57},[],{"trials":639,"activeCount":57},[],{"trials":641,"activeCount":57},[642],{"nctId":619,"briefTitle":620,"status":65,"phases":643,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":644,"interventions":645},[48],[21],[608,627],{"trials":647,"activeCount":57},[],{"trials":649,"activeCount":57},[],{"intervention":651,"totalTrials":84,"cells":652},"Vitamin B combination",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":671,"NA":673},{"trials":654,"activeCount":57},[],{"trials":656,"activeCount":57},[],{"trials":658,"activeCount":57},[],{"trials":660,"activeCount":57},[661],{"nctId":662,"briefTitle":663,"status":65,"phases":664,"primaryCompletion":665,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":670},"NCT05619328","A Prospective Clinical Trial to Evaluate the Efficacy and Safety of Neurotropic B-Vitamins in Clinically Diagnosed Peripheral Sensory Polyneuropathy of Different Etiologies.",[48],"2023-11-02","2022-09-06",323,[669],"Peripheral Sensory Neuropathy of Different Etiologies",[651],{"trials":672,"activeCount":57},[],{"trials":674,"activeCount":57},[],{"intervention":676,"totalTrials":84,"cells":677},"Investigational OTC Cream",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":697,"NA":699},{"trials":679,"activeCount":57},[],{"trials":681,"activeCount":57},[],{"trials":683,"activeCount":57},[],{"trials":685,"activeCount":57},[686],{"nctId":687,"briefTitle":688,"status":65,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT03386032","8-Week Atopic Dermatitis (AD) Treatment Study",[48],"2018-08-18","2017-11-27",65,[694],"Atopic Dermatitis Eczema",[676,696],"0.05% Desonide",{"trials":698,"activeCount":57},[],{"trials":700,"activeCount":57},[],{"intervention":696,"totalTrials":84,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":715,"NA":717},{"trials":704,"activeCount":57},[],{"trials":706,"activeCount":57},[],{"trials":708,"activeCount":57},[],{"trials":710,"activeCount":57},[711],{"nctId":687,"briefTitle":688,"status":65,"phases":712,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":713,"interventions":714},[48],[694],[676,696],{"trials":716,"activeCount":57},[],{"trials":718,"activeCount":57},[],{"intervention":720,"totalTrials":84,"cells":721},"Bifidobacterium infantis 35624",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":740,"NA":742},{"trials":723,"activeCount":57},[],{"trials":725,"activeCount":57},[],{"trials":727,"activeCount":57},[],{"trials":729,"activeCount":57},[730],{"nctId":731,"briefTitle":732,"status":65,"phases":733,"primaryCompletion":734,"completion":734,"start":735,"enrollment":736,"conditions":737,"interventions":739},"NCT00135031","Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome",[48],"2004-09","2004-01",362,[738],"Irritable Bowel Syndrome",[720],{"trials":741,"activeCount":57},[],{"trials":743,"activeCount":57},[],{"intervention":745,"totalTrials":746,"cells":747},"PG-760564",3,{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":768,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":749,"activeCount":57},[],{"trials":751,"activeCount":57},[752,761],{"nctId":753,"briefTitle":754,"status":65,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT00791817","Study to Evaluate Potential Food Effects",[46],"2006-01","2005-08",10,[23],[745,745],{"nctId":762,"briefTitle":763,"status":65,"phases":764,"primaryCompletion":756,"completion":756,"start":757,"enrollment":765,"conditions":766,"interventions":767},"NCT00791388","Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male\u002FFemale Volunteers for 14 Days",[46],45,[23],[745,745,745,745],{"trials":769,"activeCount":57},[770],{"nctId":771,"briefTitle":772,"status":65,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT00369928","Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate",[47],"2008-01","2006-08",254,[778],"Rheumatoid Arthritis",[745,745],{"trials":781,"activeCount":57},[],{"trials":783,"activeCount":57},[],{"trials":785,"activeCount":57},[],{"intervention":787,"totalTrials":84,"cells":788},"ATI-7505",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":790,"activeCount":57},[],{"trials":792,"activeCount":57},[],{"trials":794,"activeCount":57},[795],{"nctId":796,"briefTitle":797,"status":798,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":805},"NCT00501241","Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation","TERMINATED",[47],"2008-07","2007-07",214,[804],"Chronic Constipation",[787,787,787,787,787],{"trials":807,"activeCount":57},[],{"trials":809,"activeCount":57},[],{"trials":811,"activeCount":57},[],{"intervention":813,"totalTrials":84,"cells":814},"20 mg ATI 7505",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":816,"activeCount":57},[],{"trials":818,"activeCount":57},[],{"trials":820,"activeCount":57},[821],{"nctId":822,"briefTitle":823,"status":798,"phases":824,"primaryCompletion":800,"completion":800,"start":825,"enrollment":9,"conditions":826,"interventions":828},"NCT00630370","A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome",[47],"2008-02",[827],"Post Prandial Distress Syndrome",[813,829,830],"40 mg ATI 7505","80 mg ATI 7505",{"trials":832,"activeCount":57},[],{"trials":834,"activeCount":57},[],{"trials":836,"activeCount":57},[],{"intervention":829,"totalTrials":84,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":840,"activeCount":57},[],{"trials":842,"activeCount":57},[],{"trials":844,"activeCount":57},[845],{"nctId":822,"briefTitle":823,"status":798,"phases":846,"primaryCompletion":800,"completion":800,"start":825,"enrollment":9,"conditions":847,"interventions":848},[47],[827],[813,829,830],{"trials":850,"activeCount":57},[],{"trials":852,"activeCount":57},[],{"trials":854,"activeCount":57},[],{"intervention":830,"totalTrials":84,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":858,"activeCount":57},[],{"trials":860,"activeCount":57},[],{"trials":862,"activeCount":57},[863],{"nctId":822,"briefTitle":823,"status":798,"phases":864,"primaryCompletion":800,"completion":800,"start":825,"enrollment":9,"conditions":865,"interventions":866},[47],[827],[813,829,830],{"trials":868,"activeCount":57},[],{"trials":870,"activeCount":57},[],{"trials":872,"activeCount":57},[],{"intervention":874,"totalTrials":84,"cells":875},"PG-116800",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":877,"activeCount":57},[],{"trials":879,"activeCount":57},[],{"trials":881,"activeCount":57},[882],{"nctId":883,"briefTitle":884,"status":65,"phases":885,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":893},"NCT00067236","Study of Oral PG-116800 Following a Heart Attack",[47],"2004-12","2003-09",253,[890,891,892],"Myocardial Infarction","Heart Failure","Heart Enlargement",[874],{"trials":895,"activeCount":57},[],{"trials":897,"activeCount":57},[],{"trials":899,"activeCount":57},[],{"intervention":901,"totalTrials":84,"cells":902},"PG-530742",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":904,"activeCount":57},[],{"trials":906,"activeCount":57},[],{"trials":908,"activeCount":57},[909],{"nctId":910,"briefTitle":911,"status":65,"phases":912,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":918},"NCT00041756","Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis",[47],"2004-02","2002-07",395,[917],"Osteoarthritis, Knee",[901,919,920,921],"50 mg PG-530742","100 mg PG-530742","200 mg PG-530742",{"trials":923,"activeCount":57},[],{"trials":925,"activeCount":57},[],{"trials":927,"activeCount":57},[],{"intervention":919,"totalTrials":84,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":931,"activeCount":57},[],{"trials":933,"activeCount":57},[],{"trials":935,"activeCount":57},[936],{"nctId":910,"briefTitle":911,"status":65,"phases":937,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":938,"interventions":939},[47],[917],[901,919,920,921],{"trials":941,"activeCount":57},[],{"trials":943,"activeCount":57},[],{"trials":945,"activeCount":57},[],{"intervention":920,"totalTrials":84,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":949,"activeCount":57},[],{"trials":951,"activeCount":57},[],{"trials":953,"activeCount":57},[954],{"nctId":910,"briefTitle":911,"status":65,"phases":955,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":956,"interventions":957},[47],[917],[901,919,920,921],{"trials":959,"activeCount":57},[],{"trials":961,"activeCount":57},[],{"trials":963,"activeCount":57},[],{"intervention":921,"totalTrials":84,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":967,"activeCount":57},[],{"trials":969,"activeCount":57},[],{"trials":971,"activeCount":57},[972],{"nctId":910,"briefTitle":911,"status":65,"phases":973,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":974,"interventions":975},[47],[917],[901,919,920,921],{"trials":977,"activeCount":57},[],{"trials":979,"activeCount":57},[],{"trials":981,"activeCount":57},[],{"intervention":983,"totalTrials":84,"cells":984},"Doxylamine Succinate USP",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":998,"PHASE3":1000,"PHASE4":1002,"NA":1004},{"trials":986,"activeCount":57},[],{"trials":988,"activeCount":57},[989],{"nctId":990,"briefTitle":991,"status":65,"phases":992,"primaryCompletion":512,"completion":512,"start":555,"enrollment":993,"conditions":994,"interventions":997},"NCT00796315","Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children",[46],41,[995,996],"Allergic Rhinitis","Upper Respiratory Infection",[983],{"trials":999,"activeCount":57},[],{"trials":1001,"activeCount":57},[],{"trials":1003,"activeCount":57},[],{"trials":1005,"activeCount":57},[],{"intervention":1007,"totalTrials":24,"cells":1008},"Stannous fluoride toothpaste",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1010,"activeCount":57},[],{"trials":1012,"activeCount":57},[],{"trials":1014,"activeCount":57},[],{"trials":1016,"activeCount":57},[],{"trials":1018,"activeCount":57},[],{"trials":1020,"activeCount":57},[1021,1032,1043,1050],{"nctId":1022,"briefTitle":1023,"status":65,"phases":1024,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":69,"conditions":1027,"interventions":1029},"NCT03965039","A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity",[50],"2019-10-03","2019-07-08",[1028],"Dentin Hypersensitivity",[1007,1030,1031],"Potassium nitrate toothpaste","Sodium monofluorophosphate toothpaste",{"nctId":1033,"briefTitle":1034,"status":65,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1040},"NCT02574221","A Pilot Study to Evaluate a Molecular Method for Plaque",[50],"2015-10","2015-08",60,[28,15],[1041,1042],"stannous fluoride toothpaste","cavity protection toothpaste",{"nctId":1044,"briefTitle":1045,"status":65,"phases":1046,"primaryCompletion":1037,"completion":1037,"start":1047,"enrollment":1038,"conditions":1048,"interventions":1049},"NCT02543060","A Pilot Study to Evaluate a Method for Plaque When Comparing Stannous Fluoride Toothpaste to a Regular Dentifrice",[50],"2015-06",[28,15],[1041,1042],{"nctId":1051,"briefTitle":1052,"status":65,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1038,"conditions":1056,"interventions":1058},"NCT02613130","A Study to Evaluate Oral Malodor and Other Outcomes Following The Use of Two-Step Toothpaste Oral Hygiene",[50],"2015-12","2015-11",[1057],"Oral Malodor",[1007,1030],{"intervention":149,"totalTrials":24,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1062,"activeCount":57},[],{"trials":1064,"activeCount":57},[],{"trials":1066,"activeCount":57},[],{"trials":1068,"activeCount":57},[],{"trials":1070,"activeCount":57},[],{"trials":1072,"activeCount":57},[1073,1077,1081,1085],{"nctId":139,"briefTitle":140,"status":65,"phases":1074,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":1075,"interventions":1076},[],[146],[148,149,150],{"nctId":152,"briefTitle":153,"status":65,"phases":1078,"primaryCompletion":142,"completion":142,"start":143,"enrollment":155,"conditions":1079,"interventions":1080},[],[21],[148,149,150],{"nctId":159,"briefTitle":160,"status":65,"phases":1082,"primaryCompletion":142,"completion":142,"start":143,"enrollment":162,"conditions":1083,"interventions":1084},[],[15],[43,149,150],{"nctId":166,"briefTitle":167,"status":65,"phases":1086,"primaryCompletion":142,"completion":142,"start":143,"enrollment":169,"conditions":1087,"interventions":1088},[],[171],[148,149,150],{"intervention":150,"totalTrials":24,"cells":1090},{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1092,"activeCount":57},[],{"trials":1094,"activeCount":57},[],{"trials":1096,"activeCount":57},[],{"trials":1098,"activeCount":57},[],{"trials":1100,"activeCount":57},[],{"trials":1102,"activeCount":57},[1103,1107,1111,1115],{"nctId":139,"briefTitle":140,"status":65,"phases":1104,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":1105,"interventions":1106},[],[146],[148,149,150],{"nctId":152,"briefTitle":153,"status":65,"phases":1108,"primaryCompletion":142,"completion":142,"start":143,"enrollment":155,"conditions":1109,"interventions":1110},[],[21],[148,149,150],{"nctId":159,"briefTitle":160,"status":65,"phases":1112,"primaryCompletion":142,"completion":142,"start":143,"enrollment":162,"conditions":1113,"interventions":1114},[],[15],[43,149,150],{"nctId":166,"briefTitle":167,"status":65,"phases":1116,"primaryCompletion":142,"completion":142,"start":143,"enrollment":169,"conditions":1117,"interventions":1118},[],[171],[148,149,150],{"intervention":1120,"totalTrials":746,"cells":1121},"Stannous Fluoride",{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1132},{"trials":1123,"activeCount":57},[],{"trials":1125,"activeCount":57},[],{"trials":1127,"activeCount":57},[],{"trials":1129,"activeCount":57},[],{"trials":1131,"activeCount":57},[],{"trials":1133,"activeCount":57},[1134,1142,1152],{"nctId":1135,"briefTitle":1136,"status":65,"phases":1137,"primaryCompletion":1138,"completion":1138,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1141},"NCT02841839","A Study to Evaluate Sampling Methods for Subgingival Plaque",[50],"2016-06",20,[32],[1120],{"nctId":1143,"briefTitle":1144,"status":65,"phases":1145,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1139,"conditions":1148,"interventions":1150},"NCT03296657","Analysis of Stannous Fluoride in GCF and Subgingival Plaque",[50],"2017-09-22","2017-08-23",[32,1149],"GCF",[1151],"stannous fluoride",{"nctId":1153,"briefTitle":1154,"status":65,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":514,"conditions":1158,"interventions":1159},"NCT05326373","Stannous Fluoride and Gingivitis",[50],"2022-06-13","2022-04-11",[15],[1160],"Stannous fluoride",{"intervention":1162,"totalTrials":746,"cells":1163},"Stannous fluoride paste",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1165,"activeCount":57},[],{"trials":1167,"activeCount":57},[],{"trials":1169,"activeCount":57},[],{"trials":1171,"activeCount":57},[],{"trials":1173,"activeCount":57},[],{"trials":1175,"activeCount":57},[1176,1184,1193],{"nctId":1177,"briefTitle":1178,"status":65,"phases":1179,"primaryCompletion":1138,"completion":1138,"start":1055,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT02613117","Research on Oral Tolerability and Product Application\u002FResponse of Two Oxalate Products for Dental Patients With Risk of Dentinal Hypersensitivity",[50],104,[1182],"Dentinal Hypersensitivity",[1162],{"nctId":1185,"briefTitle":1186,"status":65,"phases":1187,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":557,"conditions":1190,"interventions":1191},"NCT02221349","A Clinical Study of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene",[50],"2014-10","2014-08",[18],[1192,1162],"Sodium fluoride paste",{"nctId":1194,"briefTitle":1195,"status":65,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1201},"NCT02513212","A Clinical Study to Determine the Safety and Effectiveness of Dentinal Hypersensitivity Treatment With Two Different Toothbrushes",[50],"2015-09","2015-07",24,[18],[1162],{"intervention":1203,"totalTrials":746,"cells":1204},"0.454% stannous fluoride",{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1206,"activeCount":57},[],{"trials":1208,"activeCount":57},[],{"trials":1210,"activeCount":57},[],{"trials":1212,"activeCount":57},[],{"trials":1214,"activeCount":57},[],{"trials":1216,"activeCount":57},[1217,1227,1240],{"nctId":1218,"briefTitle":1219,"status":65,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":271,"conditions":1223,"interventions":1224},"NCT05916521","A Three Month Bleeding-Model Clinical Study",[50],"2022-02-11","2021-11-15",[15],[1203,1225,1226],"0.76% sodium monofluorophosphate","0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM",{"nctId":1228,"briefTitle":1229,"status":65,"phases":1230,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1237},"NCT01549587","Oral Hygiene and Maternity Outcomes Multicenter Study (OHMOM)",[50],"2014-02","2014-04","2012-02",746,[15,1236],"Pregnancy",[1238,1203,1239],"0.243% sodium fluoride","0.07% Cetylpyridinium chloride",{"nctId":1241,"briefTitle":1242,"status":65,"phases":1243,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":271,"conditions":1246,"interventions":1247},"NCT05916508","A Bleeding-Model Clinical Study",[50],"2020-11-20","2020-10-19",[15],[1203,1225,1226],{"intervention":1030,"totalTrials":8,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1251,"activeCount":57},[],{"trials":1253,"activeCount":57},[],{"trials":1255,"activeCount":57},[],{"trials":1257,"activeCount":57},[],{"trials":1259,"activeCount":57},[],{"trials":1261,"activeCount":57},[1262,1266],{"nctId":1022,"briefTitle":1023,"status":65,"phases":1263,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":69,"conditions":1264,"interventions":1265},[50],[1028],[1007,1030,1031],{"nctId":1051,"briefTitle":1052,"status":65,"phases":1267,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1038,"conditions":1268,"interventions":1269},[50],[1057],[1007,1030],{"intervention":1042,"totalTrials":8,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1278,"PHASE4":1280,"NA":1282},{"trials":1273,"activeCount":57},[],{"trials":1275,"activeCount":57},[],{"trials":1277,"activeCount":57},[],{"trials":1279,"activeCount":57},[],{"trials":1281,"activeCount":57},[],{"trials":1283,"activeCount":57},[1284,1288],{"nctId":1033,"briefTitle":1034,"status":65,"phases":1285,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":1038,"conditions":1286,"interventions":1287},[50],[28,15],[1041,1042],{"nctId":1044,"briefTitle":1045,"status":65,"phases":1289,"primaryCompletion":1037,"completion":1037,"start":1047,"enrollment":1038,"conditions":1290,"interventions":1291},[50],[28,15],[1041,1042],{"intervention":1225,"totalTrials":8,"cells":1293},{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1304},{"trials":1295,"activeCount":57},[],{"trials":1297,"activeCount":57},[],{"trials":1299,"activeCount":57},[],{"trials":1301,"activeCount":57},[],{"trials":1303,"activeCount":57},[],{"trials":1305,"activeCount":57},[1306,1310],{"nctId":1218,"briefTitle":1219,"status":65,"phases":1307,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":271,"conditions":1308,"interventions":1309},[50],[15],[1203,1225,1226],{"nctId":1241,"briefTitle":1242,"status":65,"phases":1311,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":271,"conditions":1312,"interventions":1313},[50],[15],[1203,1225,1226],{"intervention":1226,"totalTrials":8,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1317,"activeCount":57},[],{"trials":1319,"activeCount":57},[],{"trials":1321,"activeCount":57},[],{"trials":1323,"activeCount":57},[],{"trials":1325,"activeCount":57},[],{"trials":1327,"activeCount":57},[1328,1332],{"nctId":1218,"briefTitle":1219,"status":65,"phases":1329,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":271,"conditions":1330,"interventions":1331},[50],[15],[1203,1225,1226],{"nctId":1241,"briefTitle":1242,"status":65,"phases":1333,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":271,"conditions":1334,"interventions":1335},[50],[15],[1203,1225,1226],{"intervention":203,"totalTrials":84,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1339,"activeCount":57},[],{"trials":1341,"activeCount":57},[],{"trials":1343,"activeCount":57},[],{"trials":1345,"activeCount":57},[],{"trials":1347,"activeCount":57},[],{"trials":1349,"activeCount":57},[1350],{"nctId":195,"briefTitle":196,"status":65,"phases":1351,"primaryCompletion":198,"completion":198,"start":199,"enrollment":200,"conditions":1352,"interventions":1353},[50],[15],[38,203,185,185],{"intervention":1031,"totalTrials":84,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1357,"activeCount":57},[],{"trials":1359,"activeCount":57},[],{"trials":1361,"activeCount":57},[],{"trials":1363,"activeCount":57},[],{"trials":1365,"activeCount":57},[],{"trials":1367,"activeCount":57},[1368],{"nctId":1022,"briefTitle":1023,"status":65,"phases":1369,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":69,"conditions":1370,"interventions":1371},[50],[1028],[1007,1030,1031],{"intervention":1373,"totalTrials":84,"cells":1374},"Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice",{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1383,"NA":1385},{"trials":1376,"activeCount":57},[],{"trials":1378,"activeCount":57},[],{"trials":1380,"activeCount":57},[],{"trials":1382,"activeCount":57},[],{"trials":1384,"activeCount":57},[],{"trials":1386,"activeCount":57},[1387],{"nctId":1388,"briefTitle":1389,"status":65,"phases":1390,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1395},"NCT06140758","Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ Model",[50],"2023-12-11","2023-07-31",12,[26],[1373,1396,1397,1398,1399,1400],"Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice","Toms of Maine 0 ppm Fluoride Dentifrice","Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice","1500 ppm MFP\u002FCaCO3 1.16% sodium monofluorophosphate) Dentifrice","1100 ppm (0.454% Stannous fluoride) Dentifrice",{"intervention":1396,"totalTrials":84,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1404,"activeCount":57},[],{"trials":1406,"activeCount":57},[],{"trials":1408,"activeCount":57},[],{"trials":1410,"activeCount":57},[],{"trials":1412,"activeCount":57},[],{"trials":1414,"activeCount":57},[1415],{"nctId":1388,"briefTitle":1389,"status":65,"phases":1416,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1417,"interventions":1418},[50],[26],[1373,1396,1397,1398,1399,1400],{"intervention":1397,"totalTrials":84,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1422,"activeCount":57},[],{"trials":1424,"activeCount":57},[],{"trials":1426,"activeCount":57},[],{"trials":1428,"activeCount":57},[],{"trials":1430,"activeCount":57},[],{"trials":1432,"activeCount":57},[1433],{"nctId":1388,"briefTitle":1389,"status":65,"phases":1434,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1435,"interventions":1436},[50],[26],[1373,1396,1397,1398,1399,1400],{"intervention":1398,"totalTrials":84,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1440,"activeCount":57},[],{"trials":1442,"activeCount":57},[],{"trials":1444,"activeCount":57},[],{"trials":1446,"activeCount":57},[],{"trials":1448,"activeCount":57},[],{"trials":1450,"activeCount":57},[1451],{"nctId":1388,"briefTitle":1389,"status":65,"phases":1452,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1453,"interventions":1454},[50],[26],[1373,1396,1397,1398,1399,1400],{"intervention":1399,"totalTrials":84,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1458,"activeCount":57},[],{"trials":1460,"activeCount":57},[],{"trials":1462,"activeCount":57},[],{"trials":1464,"activeCount":57},[],{"trials":1466,"activeCount":57},[],{"trials":1468,"activeCount":57},[1469],{"nctId":1388,"briefTitle":1389,"status":65,"phases":1470,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1471,"interventions":1472},[50],[26],[1373,1396,1397,1398,1399,1400],{"intervention":1400,"totalTrials":84,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1476,"activeCount":57},[],{"trials":1478,"activeCount":57},[],{"trials":1480,"activeCount":57},[],{"trials":1482,"activeCount":57},[],{"trials":1484,"activeCount":57},[],{"trials":1486,"activeCount":57},[1487],{"nctId":1388,"briefTitle":1389,"status":65,"phases":1488,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1489,"interventions":1490},[50],[26],[1373,1396,1397,1398,1399,1400],{"intervention":1492,"totalTrials":84,"cells":1493},"0 ppm Fluoride Dentifrice 1",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1495,"activeCount":57},[],{"trials":1497,"activeCount":57},[],{"trials":1499,"activeCount":57},[],{"trials":1501,"activeCount":57},[],{"trials":1503,"activeCount":57},[],{"trials":1505,"activeCount":57},[1506],{"nctId":1507,"briefTitle":1508,"status":65,"phases":1509,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":758,"conditions":1512,"interventions":1513},"NCT06140745","Evaluation of Dentifrice Formulations to Remineralize Enamel and Dentine Subsurface Lesions in a Double-Blind In-Situ Clinical Trial",[50],"2021-02-21","2020-10-05",[26],[1492,1514,1515,1516,1517],"1100 ppm NaF Fluoride Dentifrice","1500 ppm NaMFP Fluoride Dentifrice","0 ppm Fluoride Dentifrice 2","0 ppm Fluoride Dentifrice 3",{"intervention":1514,"totalTrials":84,"cells":1519},{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1521,"activeCount":57},[],{"trials":1523,"activeCount":57},[],{"trials":1525,"activeCount":57},[],{"trials":1527,"activeCount":57},[],{"trials":1529,"activeCount":57},[],{"trials":1531,"activeCount":57},[1532],{"nctId":1507,"briefTitle":1508,"status":65,"phases":1533,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":758,"conditions":1534,"interventions":1535},[50],[26],[1492,1514,1515,1516,1517],{"intervention":1515,"totalTrials":84,"cells":1537},{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1539,"activeCount":57},[],{"trials":1541,"activeCount":57},[],{"trials":1543,"activeCount":57},[],{"trials":1545,"activeCount":57},[],{"trials":1547,"activeCount":57},[],{"trials":1549,"activeCount":57},[1550],{"nctId":1507,"briefTitle":1508,"status":65,"phases":1551,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":758,"conditions":1552,"interventions":1553},[50],[26],[1492,1514,1515,1516,1517],{"intervention":1516,"totalTrials":84,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1557,"activeCount":57},[],{"trials":1559,"activeCount":57},[],{"trials":1561,"activeCount":57},[],{"trials":1563,"activeCount":57},[],{"trials":1565,"activeCount":57},[],{"trials":1567,"activeCount":57},[1568],{"nctId":1507,"briefTitle":1508,"status":65,"phases":1569,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":758,"conditions":1570,"interventions":1571},[50],[26],[1492,1514,1515,1516,1517],{"intervention":1517,"totalTrials":84,"cells":1573},{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1575,"activeCount":57},[],{"trials":1577,"activeCount":57},[],{"trials":1579,"activeCount":57},[],{"trials":1581,"activeCount":57},[],{"trials":1583,"activeCount":57},[],{"trials":1585,"activeCount":57},[1586],{"nctId":1507,"briefTitle":1508,"status":65,"phases":1587,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":758,"conditions":1588,"interventions":1589},[50],[26],[1492,1514,1515,1516,1517],{"intervention":1591,"totalTrials":84,"cells":1592},"Chlorhexidine gluconate",{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1594,"activeCount":57},[],{"trials":1596,"activeCount":57},[],{"trials":1598,"activeCount":57},[],{"trials":1600,"activeCount":57},[],{"trials":1602,"activeCount":57},[],{"trials":1604,"activeCount":57},[1605],{"nctId":1606,"briefTitle":1607,"status":65,"phases":1608,"conditions":1609,"interventions":1612},"NCT00002431","The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients",[50],[1610,1611],"Candidiasis, Oral","HIV Infections",[1591],{"intervention":1614,"totalTrials":84,"cells":1615},"China Crest® Pro-health 7 Complete Toothpaste",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1617,"activeCount":57},[],{"trials":1619,"activeCount":57},[],{"trials":1621,"activeCount":57},[],{"trials":1623,"activeCount":57},[],{"trials":1625,"activeCount":57},[],{"trials":1627,"activeCount":57},[1628],{"nctId":1629,"briefTitle":1630,"status":65,"phases":1631,"primaryCompletion":1632,"completion":1632,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT02401360","A Study to Assess Clinical Gingivitis and Microbiome Following the Use of Multiple Oral Hygiene Products",[50],"2013-04",106,[21,1635],"Dental Gingivitis",[1614,1637],"China Crest® Cavity Protection Toothpaste",{"intervention":1637,"totalTrials":84,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1641,"activeCount":57},[],{"trials":1643,"activeCount":57},[],{"trials":1645,"activeCount":57},[],{"trials":1647,"activeCount":57},[],{"trials":1649,"activeCount":57},[],{"trials":1651,"activeCount":57},[1652],{"nctId":1629,"briefTitle":1630,"status":65,"phases":1653,"primaryCompletion":1632,"completion":1632,"start":1632,"enrollment":1633,"conditions":1654,"interventions":1655},[50],[21,1635],[1614,1637],{"intervention":1192,"totalTrials":84,"cells":1657},{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1659,"activeCount":57},[],{"trials":1661,"activeCount":57},[],{"trials":1663,"activeCount":57},[],{"trials":1665,"activeCount":57},[],{"trials":1667,"activeCount":57},[],{"trials":1669,"activeCount":57},[1670],{"nctId":1185,"briefTitle":1186,"status":65,"phases":1671,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":557,"conditions":1672,"interventions":1673},[50],[18],[1192,1162],{"intervention":1238,"totalTrials":84,"cells":1675},{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1677,"activeCount":57},[],{"trials":1679,"activeCount":57},[],{"trials":1681,"activeCount":57},[],{"trials":1683,"activeCount":57},[],{"trials":1685,"activeCount":57},[],{"trials":1687,"activeCount":57},[1688],{"nctId":1228,"briefTitle":1229,"status":65,"phases":1689,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":1690,"interventions":1691},[50],[15,1236],[1238,1203,1239],{"intervention":1239,"totalTrials":84,"cells":1693},{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1695,"activeCount":57},[],{"trials":1697,"activeCount":57},[],{"trials":1699,"activeCount":57},[],{"trials":1701,"activeCount":57},[],{"trials":1703,"activeCount":57},[],{"trials":1705,"activeCount":57},[1706],{"nctId":1228,"briefTitle":1229,"status":65,"phases":1707,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":1708,"interventions":1709},[50],[15,1236],[1238,1203,1239],{"intervention":1711,"totalTrials":84,"cells":1712},"Marketed Dentifrice",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1723},{"trials":1714,"activeCount":57},[],{"trials":1716,"activeCount":57},[],{"trials":1718,"activeCount":57},[],{"trials":1720,"activeCount":57},[],{"trials":1722,"activeCount":57},[],{"trials":1724,"activeCount":57},[1725],{"nctId":1726,"briefTitle":1727,"status":65,"phases":1728,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":271,"conditions":1731,"interventions":1733},"NCT02409836","A Study to Assess the Ingestion of Dentifrice by Children",[50],"1993-07","1993-05",[1732],"Healthy Individuals",[1711,1734,1734],"Marketed Flavored Dentifrice",{"intervention":1734,"totalTrials":84,"cells":1736},{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1743,"PHASE4":1745,"NA":1747},{"trials":1738,"activeCount":57},[],{"trials":1740,"activeCount":57},[],{"trials":1742,"activeCount":57},[],{"trials":1744,"activeCount":57},[],{"trials":1746,"activeCount":57},[],{"trials":1748,"activeCount":57},[1749],{"nctId":1726,"briefTitle":1727,"status":65,"phases":1750,"primaryCompletion":1729,"completion":1729,"start":1730,"enrollment":271,"conditions":1751,"interventions":1752},[50],[1732],[1711,1734,1734]]